Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo - Acoramidis significantly ...